Manufacturer
257 recalls in our database name Hospira, Inc. as the manufacturing or recalling firm.
Of the 257 recalls from Hospira, Inc. we have scored against our rubric, 18 (7%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 104 (40%) are Severe.
Which agencies issued them
The manufacturer string comes from the agency’s own source notice — for FDA recalls, the “recalling firm” field; for NHTSA recalls, the vehicle manufacturer; for CPSC recalls, the firm-of-record on the joint press release. A single corporate family can appear under multiple manufacturer strings as agency notices aren’t standardized on a canonical name. If you don’t see recalls you expect, try a parent-company search or a broader full-text search.
Severity scores below are computed from the agency’s classification and the recall text, never from manufacturer behaviour or history. Many manufacturers issue routine corrective actions (software updates, labelling corrections) that are correctly scored low — having recalls on this list isn’t inherently a quality signal.
Hospira Inc. is recalling 72,300 vials of Diazepam Injection due to ineffective crimps that may compromise sterility.
Hospira, Inc. is recalling 345,800 vials of Ketorolac Tromethamine Injection due to a lack of assurance of sterility caused by loose or missing crimps on fliptop vials.
Hospira is recalling 94,110 vials of Propofol Injectable Emulsion because a single stainless steel particulate was found during inspection.
Hospira Inc. is recalling 0.9% Sodium Chloride Injection, USP, 1000 mL containers due to the presence of small grey/brown brass particulates.
Hospira Inc. is recalling 1,104 Y-type blood sets because the piercing pin may puncture the outer wall of blood bags during insertion.
Hospira is recalling 1,976 Y-type blood sets because the piercing pin may puncture the outer wall of blood bags during insertion.
Hospira is recalling 240 blood sets because the piercing pin may puncture the outer wall of blood bags during insertion.
Hospira Inc. is recalling 3,600 units of Y-Type Blood Sets because the piercing pin may puncture the outer wall of blood bags during insertion.
Hospira is recalling 1,152 blood sets because the piercing pin may puncture the outer wall of blood bags during insertion.
Hospira Inc. is recalling 96 units of PLUM BLOOD SETS because the piercing pin may puncture the outer wall of blood bags during insertion.
Hospira Inc. is recalling 672 units of secondary blood sets because the piercing pin may puncture the outer wall of blood bags during insertion.
Hospira is recalling specific blood sets because the piercing pin may puncture the outer wall of blood bags during insertion.
Hospira is recalling 340,600 vials of Ondansetron Injection due to the discovery of particulate matter in a preceding lot.
Hospira Inc. is recalling specific blood sets because the piercing pin may puncture the outer wall of blood bags during insertion.
Hospira Inc. is recalling 2,791 Symbiq Infusion Systems because the secondary audio signal fails to activate. The devices were distributed across 22 US states.
Hospira is recalling 268,700 vials of Sodium Chloride Injection, USP, 0.9% due to a confirmed report of visible particulate matter embedded in the plastic vial.
Hospira is recalling Symbiq IV pump sets because a defective ball valve may fail to seal, causing air-in-line alarms during fluid administration.
Hospira Inc. is recalling 168,300 vials of Gentamicin Sulfate Injection USP 80 mg/2 mL because visible particles were found floating in the primary container.
Hospira is voluntarily recalling 0.9% Sodium Chloride Irrigation bags due to possible leaking that compromises sterility.
Hospira is voluntarily recalling 14,706 units of 70% Dextrose Injection USP due to possible leaking bags that may compromise sterility.
Hospira is voluntarily recalling 0.45% Sodium Chloride Injection due to possible leaking bags that may compromise sterility.
Hospira is voluntarily recalling 1.5% Glycine Irrigation, USP, 3000 mL, due to possible leaking bags that may compromise sterility.
Hospira is voluntarily recalling 0.9% Sodium Chloride Injection in flexible containers due to possible leaking bags that may compromise sterility.
Hospira Inc. is voluntarily recalling 74,256 units of 5% Dextrose and 0.45% Sodium Chloride Injection due to possible leaking bags that may compromise sterility.
Hospira is voluntarily recalling 5% Dextrose Injection USP bags due to possible leaking that compromises sterility assurance.
Community-sourced company facts from Wikidata, not from any recall agency. This is background on the corporate entity — it says nothing about the recall(s) listed on this page, which come from the agency source notice above.
Hospira
American pharmaceutical company
Source: Wikidata (Q1470525), licensed CC0. Wikidata is community-edited and may not reflect the current corporate structure.